Titre (en)
Exploration
Accueil
Racine
Exploration
Accueil

Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « Titre (en) » - entrée « events »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
event < events < every  Facettes :

List of bibliographic references indexed by events

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000001 (2021) Daniel G. Dauner ; Kim Nichols DaunerSummary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.
000306 (2021) Pobitra Borah [Inde] ; Pran Kishore Deb [Jordanie] ; Balakumar Chandrasekaran [Jordanie] ; Manoj Goyal [Arabie saoudite] ; Monika Bansal [Arabie saoudite] ; Snawar Hussain [Arabie saoudite] ; Pottathil Shinu [Arabie saoudite] ; Katharigatta N. Venugopala [Afrique du Sud] ; Nizar A. Al-Shar'I [Jordanie] ; Satyendra Deka [Inde] ; Vinayak Singh [Afrique du Sud]Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted.
000324 (2021) S. Verheijen [Pays-Bas] ; M. Van Luin [Pays-Bas] ; R J Brüggemann [Pays-Bas] ; Q. De Mast [Pays-Bas] ; R J Hassing [Pays-Bas] ; D M Burger [Pays-Bas]More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine.
000468 (2021) Michael Dörks [Allemagne] ; Kathrin Jobski [Allemagne] ; Falk Hoffmann [Allemagne] ; Antonios Douros [Canada, Allemagne]Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.
000515 (2021) Christian Skalafouris [Suisse] ; Caroline Samer [Suisse] ; Jerome Stirnemann [Suisse] ; Olivier Grosgurin [Suisse] ; François Eggimann [Suisse] ; Damien Grauser [Suisse] ; Jean-Luc Reny [Suisse] ; Pascal Bonnabry [Suisse] ; Bertrand Guignard [Suisse]Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
000611 (2021) Mary Kelly [Irlande (pays)] ; R Isìn O'Connor [Irlande (pays)] ; Liam Townsend [Irlande (pays)] ; Miriam Coghlan [Irlande (pays)] ; Eileen Relihan [Irlande (pays)] ; Miriam Moriarty [Irlande (pays)] ; Bernard Carr [Irlande (pays)] ; Gail Melanophy [Irlande (pays)] ; Caitriona Doyle [Irlande (pays)] ; Ciaran Bannan [Irlande (pays)] ; Ruth O'Riordan [Irlande (pays)] ; Concepta Merry [Irlande (pays)] ; Susie Clarke [Irlande (pays)] ; Colm Bergin [Irlande (pays)]Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
000653 (2021) Adam Goldman [Israël] ; David Bomze [Israël, Suisse] ; Rachel Dankner [Israël] ; Hanoch Hod [Israël] ; Tomer Meirson [Israël] ; Ben Boursi [Israël, États-Unis] ; Elad Maor [Israël]Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
000662 (2021) Christian A. Devaux [France] ; Laurence Camoin-Jau [France] ; Jean-Louis Mege [France] ; Didier Raoult [France]Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
000862 (2020) Amit Dang [Inde] ; B N Vallish [Inde] ; Sumit Dang [États-Unis]Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events.
000C23 (2020) Ramy Abdelmaseih [États-Unis] ; Randa Abdelmasih [États-Unis] ; Mustajab Hasan [États-Unis] ; Srikanth Tadepalli [États-Unis] ; Jigar Patel [États-Unis]Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
000C81 (2020) Sweilem B. Al Rihani [États-Unis] ; Matt K. Smith [États-Unis] ; Ravil Bikmetov [États-Unis] ; Malavika Deodhar [États-Unis] ; Pamela Dow [États-Unis] ; Jacques Turgeon [États-Unis, Canada] ; Veronique Michaud [États-Unis, Canada]Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy.
000D95 (2020) Stip Emmanuel [Émirats arabes unis] ; Linda Östlundh [Émirats arabes unis]Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic.
000F34 (2020) Kenichiro Sato [Japon] ; Tatsuo Mano [Japon] ; Atsushi Iwata [Japon] ; Tatsushi Toda [Japon]Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
001245 (2020) Bada Sharanappa Nagaraja [Inde] ; Kalhalli Narayanaswamy Ramesh [Inde] ; Debjyoti Dhar [Inde] ; Mahammad Samim Mondal [Inde] ; Treshita Dey [Inde] ; Subhrakamal Saha [Inde] ; Mumtaz Ali Khan [Inde] ; Shah Dhiren Rutul [Inde] ; Kishore Pratik [Inde] ; Jayaram Manjula [Inde] ; Thuppanattumadam Ananthasubramanian Sangeeth [Inde] ; Vikram Singh [Inde]HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
001685 (2020) Isaac V. Cohen [États-Unis] ; Tigran Makunts [États-Unis] ; Talar Moumedjian [États-Unis] ; Masara A. Issa [États-Unis] ; Ruben Abagyan [États-Unis]Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
001939 (2020) Adam Kilian [États-Unis] ; Yu Pei Chock [États-Unis] ; Irvin J. Huang [États-Unis] ; Elizabeth R. Graef [États-Unis] ; Laura A. Upton [États-Unis] ; Aneka Khilnani [États-Unis] ; Sonia D Silinsky Krupnikova [États-Unis] ; Ibrahim Almaghlouth [Arabie saoudite] ; Laura C. Cappelli [États-Unis] ; Ruth Fernandez-Ruiz [États-Unis] ; Brittany A. Frankel [États-Unis] ; Jourdan Frankovich [États-Unis] ; Carly Harrison ; Bharat Kumar [États-Unis] ; Kanika Monga [États-Unis] ; Jorge A Rosario Vega [États-Unis] ; Namrata Singh [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Elaine Sullo [États-Unis] ; Kristen J. Young [États-Unis] ; Ali Duarte-Garcia [États-Unis] ; Michael Putman [États-Unis] ; Sindhu Johnson [Canada] ; Rebecca Grainger [Nouvelle-Zélande] ; Zachary S. Wallace [États-Unis] ; Jean W. Liew [États-Unis] ; Aruni Jayatilleke [États-Unis]Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "events" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "events" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    events
}}
Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021